KYSE-30-luc Orthotopic Mouse Model Service for Esophageal Cancer

The KYSE-30-luc orthotopic mouse model pairs a luciferase-labeled human esophageal squamous cell carcinoma line with implantation into the native esophageal wall, allowing tumor growth, local invasion, and treatment response to be tracked in real time through non-invasive bioluminescence imaging. Drawing on proven surgical techniques and quantitative imaging expertise, Alfa Cytology supplies end-to-end support for KYSE-30-luc orthotopic model construction, serial monitoring, histopathological validation, and preclinical efficacy testing.

Overview of KYSE-30-luc Orthotopic Mouse Model for Esophageal Cancer

KYSE-30-luc is the bioluminescent derivative of KYSE-30, one of the best-known members of the KYSE panel of human esophageal squamous cell carcinoma (ESCC) lines established at Kyoto University from a well-differentiated tumor of a 64-year-old untreated Japanese male patient. The parental line grows rapidly (doubling time around 20.8 hours) and carries an extensively characterized genome that includes a TP53 intron-6 splice mutation, a HRAS p.Gln61Leu mutation, a truncating CDKN2A (p16) alteration, amplification of MYC, CCND1, and HER2, and exceptionally high EGFR expression. To convert this line into a trackable imaging tool, KYSE-30 cells are engineered to stably express firefly luciferase — introduced with a pLVX-Luciferase vector, enriched under stepwise G418 selection, and confirmed for strong luciferase activity by dual-luciferase reporter assay in vitro — without compromising their tumorigenic behavior.

Fig 1. The luminescent intensity increased with the growth of the implanted tumor. (Song, Shuai, et al., 2014)

The real value of the luciferase tag emerges when the cells are returned to their organ of origin. Injected into the muscularis externa of the abdominal esophagus near the diaphragm, KYSE-30-luc cells form tumors with a 100% take rate, and because the emitted photons scale with viable tumor mass, whole-body imaging captures tumor initiation and progression in vivo week by week without sacrificing animals. Histologically, these orthotopic tumors faithfully mirror human ESCC: nodular growth causing esophageal luminal stricture, invasion through the adventitia, lymphovascular invasion, and perineural infiltration. The platform's utility has been demonstrated functionally as well — AKT shRNA knockdown cells showed significantly suppressed orthotopic tumor growth compared with controls, underscoring its value for gene-function studies, metastasis research, and therapeutic regimen testing in a physiologically relevant microenvironment.

Cell Line Information: KYSE-30-luc

KYSE-30-luc combines the deeply annotated biology of the parental KYSE-30 line with a validated firefly luciferase reporter, creating an imaging-ready ESCC tool for orthotopic studies. Its key attributes are listed below.

Our Services

Alfa Cytology equips researchers with a turnkey KYSE-30-luc orthotopic solution: authenticated luciferase-positive cells, precision intramural implantation surgery, scheduled IVIS imaging with quantitative signal analysis, and terminal histopathology — all executed under one quality-managed preclinical workflow.

Workflow of KYSE-30-luc Orthotopic Mouse Model Construction

The KYSE-30-luc orthotopic model is established by direct microinjection of luciferase-labeled cells into the esophageal wall, followed by serial whole-body bioluminescence imaging. The workflow typically proceeds as follows.

1. Luciferase labeling and clone selection: KYSE-30 cells are transfected with pLVX-Luciferase plasmids, placed under stepwise G418 selection to enrich luciferase-positive cells, and isolated as stable clones.
2. Reporter verification and quality control: Luciferase activity is quantified by dual-luciferase reporter assay, and cell identity is confirmed by STR profiling with mycoplasma testing before expansion.
3. Inoculum preparation: KYSE-30-luc cells are expanded in RPMI 1640 with 10% FBS, harvested during exponential growth, counted, and resuspended in plain medium at a working concentration delivering 2 × 10⁵ cells in 10 μL per mouse.
4. Anesthesia and surgical exposure: Athymic nude mice are anesthetized and positioned supine; a small upper-abdominal incision is made, retractors hold the wound open, the left liver lobe is gently raised, and caudal traction on the stomach straightens the abdominal esophagus for clear visualization under a dissecting microscope.
5. Intramural microinjection: Using a 30-gauge insulin syringe, the cell suspension is injected into the muscularis externa of the esophagus; formation of a local edema at the injection site confirms correct intramural delivery, and a cotton swab is pressed on the site as the needle is withdrawn to prevent leakage into the peritoneal cavity.
6. Closure and postoperative care: The peritoneum is closed with Vicryl absorbable sutures and the skin with wound clips; mice are warmed until fully mobile and monitored daily for body weight, hydration, appetite, and behavior.
7. Serial imaging and endpoint analysis: Tumor growth is monitored weekly by IVIS bioluminescence imaging after intraperitoneal D-luciferin (150 mg/kg) in vivo; at study end, orthotopic tumors are excised, weighed, and processed for H&E histology to confirm adventitia invasion, lymphovascular invasion, and perineural infiltration.

Fig 2. KYSE-30-luc orthotopic mouse model construction workflow.

Case Study-KYSE-30-luc Orthotopic Mouse Model Development

Alfa Cytology has implemented the KYSE-30-luc orthotopic platform in several preclinical programs covering imaging-based model development, longitudinal efficacy tracking of investigational agents, and signaling-pathway interrogation. In these projects, luciferase signal kinetics in vivo provided early, quantitative readouts of tumor growth, while terminal histopathology confirmed characteristic ESCC invasion patterns. Project specifics and tailored study designs can be discussed upon request.

Why Choose Alfa Cytology?

A luciferase-tagged orthotopic model succeeds or fails on two things — the quality of the labeled cells and the precision of the surgery — and Alfa Cytology is structured to deliver both at a consistently high standard.

• Validated KYSE-30-luc cells with documented high luciferase activity and confirmed parental-line identity through STR profiling.
• Microsurgical expertise for intramural esophageal injection, the step that determines take rate and anatomical fidelity in this model.
• Quantitative, scheduled bioluminescence imaging that turns tumor burden in vivo into objective, analyzable data.
• Published-method alignment: workflow parameters follow the conditions reported to achieve 100% orthotopic tumorigenicity for this line.
• Flexible study configurations for monotherapy, combination regimens, gene knockdown, and mechanism-of-action endpoints.
• Single-point project management from cell banking through imaging, histopathology, and final data delivery.

Contact Us

If your esophageal cancer program needs real-time, quantitative tumor monitoring in a true orthotopic setting, the KYSE-30-luc model is an excellent place to start. Reach out to us to discuss your targets and timelines, and Alfa Cytology will assemble a preclinical plan designed around your goals.

For research use only. Not intended for any clinical use.